<DOC>
	<DOCNO>NCT02501018</DOCNO>
	<brief_summary>A prospective , open label , control , randomize , double arm , multi-center study assess efficacy safety CLBS12 patient critical limb ischemia ( CLI ) due arteriosclerosis obliterans ( ASO ) single arm sub-study ass safety potential efficacy CLBS12 patient CLI due Buerger 's Disease ( BD ) .</brief_summary>
	<brief_title>Study Assess Efficacy Safety CLBS12 Patients With Critical Limb Ischemia ( CLI )</brief_title>
	<detailed_description>Main ASO Study : This study compare safety efficacy intramuscular transplantation autologous CD34+ cell ( CLBS12 ) plus standard care ( SOC ) pharmacotherapy ( cell treatment arm ) versus SOC pharmacotherapy alone ( e.g. , antiplatelets , anticoagulant , vasodilator include prostanoids ) ( control arm ) subject CLI categorize Rutherford score 4 5 due ASO age 20 80 year endovascular surgical revascularization option . Subjects assign cell treatment arm continue SOC pharmacotherapy also receive subcutaneous injection GRAN® 5 ug/kg/day 5 day undergo apheresis last day GRAN® administration . Then subject cell treatment arm receive intramuscular injection autologous CD34+ cell . Subjects assign control arm continue receive SOC pharmacotherapy alone possibility receive cell treatment via rescue option . BD Substudy : A single arm substudy include assess safety efficacy intramuscular transplantation CLBS12 patient ( N=~5 ) CLI categorize 4 5 Rutherford score due BD age 20 80 year . Subjects give inform consent screen eligibility within 28 day registration . Subjects continue SOC pharmacotherapy also receive subcutaneous injection GRAN® 5 µg/kg/day 5 day ( Pretreatment Days 1 5 ) mobilize CD34+ cell peripheral blood undergo apheresis pretreatment Day 5 collect CD34+ cell . The choice pharmacotherapy make investigator . Each subject cell treatment arm receive intramuscular injection 1 × 10^6 autologous CD34+ cells/kg/limb . All subject evaluate efficacy safety assessment approximately 12 month . Efficacy assessment include CLI free status , AFS , PFS , ABI , TBI , SPP , TcPO2 , ICD , VAS , AQA .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Arteriosclerosis Obliterans</mesh_term>
	<criteria>subject CLI cause ASO BD &lt; 20 year old</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>CLI</keyword>
</DOC>